Natural history study for Sanfilippo type C disease
Part of Genetic & congenital, Hormones & metabolism, Skin clinical trials.
This study follows people with Sanfilippo syndrome type C to better understand how the disease changes over time. It does not appear to test a new medicine; instead, it collects health and development information that can help future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Confirmed Sanfilippo type C based on specific enzyme testing and genetic (DNA) results for the HGSNAT gene
- Evidence of extra sugar-like material in urine (called GAG/HS) from Sanfilippo type C
- A parent or legal guardian can sign consent (and the child agrees if needed)
- A parent or legal guardian can bring the child to every study visit
- Child can eat or drink by mouth and can walk with or without help
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with MPS IIIC over time to learn more about how the disease progresses. It does not test a new treatment, but the information may help with future care and research.
This trial tests a one-time gene therapy injection for children with Sanfilippo syndrome type B (MPS IIIB), a condition that affects the brain and development. The goal is to see if adding a healthy gene can slow or stop the disease.
This study tests whether a cannabis-derived medicine called cannabidiol (CBD) can help children with Sanfilippo syndrome, a rare genetic disorder. It may be a good fit for children who have already tried other treatments or whose disease is more advanced.
This program provides early access to an experimental enzyme therapy given directly into the brain for children with Sanfilippo syndrome type B, a genetic condition that affects the nervous system. The treatment aims to replace a missing enzyme to slow or stabilize symptoms.
This trial is testing an experimental treatment given directly into the fluid around the brain to replace a missing enzyme in children with Sanfilippo syndrome type B. It aims to see if the treatment can slow or improve some symptoms of the disease.
This study follows people with MPS IIIA (Sanfilippo syndrome type A) who have received or plan to receive the gene therapy rebisufligene etisparvovec, to monitor their health and treatment effects over time.
Hear when a new Sanfilippo Syndrome Type C trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.